Patient Guide · Treatment & Care

Treatment for Schwannomatosis

Pain management and watchful waiting are not a failure of medicine. They are its honest answer for now — and understanding why matters, because the alternative can cause more harm than the disease.

The Current Standard of Care

There is no cure for schwannomatosis. There is no drug that stops tumor formation. There is no surgery that addresses the underlying biology. What currently exists is management — and management, done well, is not nothing.

Most SWN patients are cared for through two tracks that run in parallel.

Track 1

Pain Management

Schwannomatosis pain is not a single mechanism — it is several running simultaneously. Tumor pressure on nerves, tumor-secreted cytokines sensitizing surrounding tissue, central nervous system amplification of chronic input, and peripheral nerve hyperexcitability all contribute (Gutierrez C et al., Journal of Pain, 2026). No single medication addresses all of these. Effective pain management in SWN usually means finding the right combination of tools for a specific patient’s specific pattern.

Neuropathic agents — gabapentin (Neurontin), pregabalin (Lyrica), duloxetine (Cymbalta), and tricyclic antidepressants are commonly used, with variable results across patients
Opioids — addressed in detail in the opioids section below. The picture is more complicated than the standard dismissal suggests.
Interventional pain management — nerve blocks, epidural steroid injections, and spinal cord stimulation for patients with specific tumor locations and refractory pain
Multidisciplinary pain care — pain psychology, physical therapy, occupational therapy, and adaptive strategies. Pain that cannot be eliminated can sometimes be made livable through the full spectrum of tools.

Track 2

Tumor Surveillance

Schwannomas in SWN patients are monitored, not automatically removed. The goal of surveillance is to catch functional threats early — before a tumor causes spinal cord compression, hearing loss, or other irreversible harm — without acting prematurely on tumors that are stable and not yet causing problems.

MRI imaging — typically annually or every two to three years when stable. Whole-spine MRI is standard; brain MRI is included for subtypes at risk for intracranial tumors (particularly NF2-SWN and SWN-SMARCB1). Imaging frequency is adjusted based on subtype, tumor burden, and symptom changes (Evans DG et al., ERN GENTURIS, European Journal of Human Genetics, 2022).
Annual neurologic examination — tracking strength, sensation, reflexes, and functional status over time. Changes between visits are often the most important signal.
Symptom reporting — patients are the first line of detection. New or worsening focal pain, weakness, numbness, or bowel/bladder changes should prompt evaluation outside the normal surveillance cycle.

Surveillance is not passive. It is a clinical strategy.

✦

Why Surgery Is Not Usually the Answer

When a patient is told they have multiple tumors and the plan is “watch and manage,” the question that follows is almost always the same: why can’t you just remove them?

It is a reasonable question. The answer requires understanding what schwannomatosis actually is — not just what it produces.

Surgery does not fix the biology

Schwannomatosis is a genetic condition. The gene change that caused one tumor will cause others. A patient who has five tumors removed today may develop five more — or ten more — over the next decade. Surgery addresses a single tumor. It does not change what the body will do next.

Tumors grow on nerves — and the nerve must be preserved

Schwannomas arise from Schwann cells, which wrap around peripheral nerves. The tumor and the nerve are anatomically intertwined. Removing a schwannoma means working around, or sometimes within, the nerve itself. The surgeon’s goal is always function-preservation — but permanent numbness, weakness, or loss of function at the surgical site is a documented risk even in the most experienced hands. A patient can leave surgery with new deficits that were not present before the procedure.

Surgery can create new pain

Operating on a nerve-associated tumor carries the risk of neuroma formation — a painful tangle of nerve fibers at the surgical site. Post-surgical neuropathic pain is a documented complication of peripheral nerve surgery and can be as difficult to treat as the original tumor pain. In some patients, surgical pain replaces tumor pain without meaningfully improving quality of life.

Many tumors are in inaccessible locations

Not all schwannomas are reachable without unacceptable risk. Tumors on spinal nerve roots, deep within the retroperitoneum, adjacent to major vessels, or near cranial nerves require surgical expertise that is rare and carry procedural risks that change the risk/benefit calculation significantly. Not every location allows for safe resection, even with excellent surgical technique.

Surgical risk accumulates across a lifetime

Each surgery carries anesthesia risk, infection risk, healing demands, and recovery time. A patient managing a disease that produces tumors throughout their lifetime cannot sustain a surgical approach to each one. The cumulative burden of multiple procedures — across years of an already physically demanding illness — can exceed the benefit.

Incomplete resection leads to regrowth

Schwannomas that are partially removed often regrow. The surgical goal is complete resection, but nerve preservation sometimes means leaving tumor behind. Regrowth at a previously operated site can be more technically challenging to address than the original surgery — with scar tissue, altered anatomy, and additional nerve risk.

The decision not to operate is not a clinician giving up. It is a clinician doing the risk/benefit calculation correctly — and choosing to preserve what the patient currently has.

✦

When Surgery Is the Right Answer

Surgery is not off the table — it is saved for the situations where its benefits clearly outweigh its risks. In those moments, it is the right intervention, and it matters enormously that it is performed by a surgeon with specific experience in peripheral nerve tumors.

Functional threat

A tumor compressing the spinal cord or a nerve root — causing weakness, loss of sensation, or bowel and bladder dysfunction — warrants surgical evaluation. When function is actively at risk, the calculus changes.

Rapid or suspicious growth

A schwannoma that grows quickly over weeks (not years), or is accompanied by escalating focal pain no longer controlled by previous management, requires urgent evaluation. In SWN-SMARCB1 especially, rapid growth raises concern for malignant transformation.

Vital structure involvement

A tumor threatening an airway, major vessel, or critical anatomical structure may require surgical intervention regardless of other factors. Location alone can determine necessity.

Dominant single-tumor burden

Occasionally a patient has one tumor that is the clear primary driver of their pain and disability, in a location amenable to surgery, with a risk profile that favors intervention. This exists — it is just less common than patients initially expect.

If surgery is recommended: The surgeon matters as much as the decision. Schwannomas grow on nerves. Ask specifically how many peripheral nerve tumors this surgeon has removed, and whether they have experience with schwannomatosis. This is worth traveling for. Find an NF specialist →

✦

Pain Management: Finding the Right Specialist

Schwannomatosis pain is neuropathic — it operates through mechanisms that standard pain medications don’t reach. A primary care physician is not trained to manage it at the level SWNs need, and expecting them to is one of the most common reasons SWN patients spend years inadequately treated.

A pain management specialist is not a luxury. It is a core member of your care team, and getting there sooner changes outcomes.

Your neurologist manages your tumors. A pain management specialist manages your pain. These are different jobs. Many SWN patients spend years asking their neurologist to do the job of a pain specialist — a reasonable mistake when no one has explained the distinction. Both matter, and both should be on your team.

How to Find a Pain Management Specialist

Ask your NF clinic or neurologist for a referral

Specifically request a pain specialist with experience in neuropathic or nerve-tumor-related pain. NF specialty centers often have established relationships with pain programs — ask directly. If your neurologist is currently managing your pain medications, ask whether a dedicated pain consultation would be appropriate.

Look for board-certified pain physicians

Board certification in Pain Medicine can come through the American Board of Anesthesiology, Physical Medicine & Rehabilitation, or as a subspecialty through neurology or psychiatry. The credential matters: it signals dedicated training in pain as a specialty, not pain medications managed alongside a general practice.

Seek a multidisciplinary pain clinic at an academic center

Academic medical centers with integrated pain programs offer more options than private pain management practices — including interventional procedures, pain psychology, and physical therapy under one roof. If the closest pain clinic primarily manages post-surgical or musculoskeletal pain, it may not have the tools your condition requires.

You may need to travel — and that is worth knowing early

Like NF specialty care, pain management equipped for neuropathic tumor pain is not everywhere. This is part of the disease burden. Planning for it early is better than discovering it after waiting months for an appointment that wasn’t the right fit.

What Most SWN Patients Are Actually Using

These approaches represent the honest reality of current SWN pain management — not all formally studied in schwannomatosis specifically, but what patients are being prescribed, what is helping some people, and what the patient community has learned from experience.

Neuropathic agents

Gabapentin (Neurontin) and pregabalin (Lyrica) are the most common starting points. Duloxetine (Cymbalta) and tricyclic antidepressants (amitriptyline, nortriptyline) are used when gabapentinoids don’t provide enough relief or cause too many side effects. Response varies significantly between patients.

Nerve blocks and ketamine infusions

Nerve blocks provide targeted, temporary relief for specific tumor locations — sometimes lasting weeks to months. Ketamine infusions are used for refractory neuropathic pain; some SWN patients report significant relief, though effects are not permanent and access varies by region.

Off-label and emerging options

Low-dose naltrexone (LDN) is used off-label and anecdotally reported as helpful by a subset of SWN patients. Medical cannabis is used in legal states for pain and sleep. Anti-CGRP therapy (erenumab/Aimovig) and anti-IL-6 therapy (siltuximab/Sylvant) are currently being tested in the STARFISH trial (ClinicalTrials.gov: NCT05684692) — these are not available as standard treatments outside of the trial.

Physical and behavioral adjuncts

Heat, cold, TENS units, physical therapy, occupational therapy, and pain psychology don’t replace medication management — but they can meaningfully reduce flares and improve daily function. Pain psychology is supported by evidence for quality of life in chronic pain and is significantly underused in the SWN patient community.

On Opioids: An Honest Conversation

The standard line is that opioids don’t work for neuropathic pain — that they’re designed for a different mechanism and are therefore the wrong tool. That framing is incomplete for schwannomatosis, and patients deserve a more honest account of what opioids do, what they don’t do, and why some SWN patients use them under specialist supervision with real functional benefit.

What opioids actually do

Opioids don’t act on peripheral pain signals directly. They work centrally — in the brain and spinal cord — by activating the descending inhibitory pathway, which reduces how loudly the nervous system amplifies incoming pain. They turn down the volume on the processing system.

SWN pain has both a peripheral component (tumor-secreted cytokines activating mechanosensitive channels at the nerve endings — Gutierrez C et al., Journal of Pain, 2026) and a central component (a nervous system that has been running at high gain for years and has literally reorganized around chronic pain input). Opioids address the central component. For a patient whose baseline pain is driven significantly by central sensitization, that is not nothing — it can be the difference between a pain level that allows some function and one that does not.

Some SWN patients, including those with high tumor burden or severe refractory pain, use extended-release opioids or transdermal delivery (patches) under neurologist supervision specifically to maintain a functional baseline. The goal is not sedation. It is function. A responsible specialist evaluates this by functional outcome: can this patient do more with it than without it?

Physical dependence is not addiction

This distinction matters and is almost never explained clearly to patients.

Physical dependence means your body has adapted to a medication and requires tapering to stop safely rather than stopping abruptly. This is true of SSRIs, gabapentin, pregabalin, corticosteroids, beta-blockers — and opioids. It is a pharmacological property of the medication, not a character flaw or a disease state. If you have been on any of these medications long-term and cannot simply stop them overnight without consequences, you are physically dependent. That is expected and managed medically.

Addiction (substance use disorder) is a behavioral pattern characterized by compulsive use despite harm, inability to control use, and the substance reorganizing your life around obtaining it. It has neurobiological roots and is a treatable condition — but it is a different thing entirely from physical dependence.

Chronic pain patients on long-term opioids under medical supervision develop physical dependence. Most are not addicted. The medical community knows this distinction clearly. The cultural stigma around opioids collapses it deliberately and harmfully — leaving patients undertreated, ashamed to ask, and sometimes managing severe pain at unnecessarily high levels because they have internalized a stigma that was never theirs to carry.

A SWN patient who has used opioids for years, under neurologist supervision, to maintain enough function to work or care for their family is not an addict. They are a person with severe chronic pain using one of the available tools appropriately.

What opioids cannot do in SWN

Opioids do not address the peripheral mechanism — the tumor-secreted cytokines directly activating Piezo channels in nerve endings (Gutierrez C et al., Journal of Pain, 2026). That signal is generated outside the central nervous system, where opioids don’t operate. This is why breakthrough pain events can still occur in patients on opioids, and why research into GsMTx-4 and other peripherally-acting compounds matters: it targets the part of SWN pain that opioids miss.

The honest picture is that SWN pain requires multiple tools aimed at different parts of the circuit. Opioids are one legitimate tool for one part of that circuit. They are neither a cure nor a reason for shame.

✦

Also in this guide

Living With Schwannomatosis

What the disease actually takes away — what becomes impossible, what becomes harder, what requires complete reinvention. Clothing, sleep, pacing, work, relationships, and how to advocate for yourself in medical settings.

Read it →

✦

The Research That Matters

The reason pain management and watchful waiting are the current standard is not that researchers have given up. It is that the science is hard, the disease is rare, and the tools to do better are still being built. The tools being built are real — and the people building them are working on the right problems.

Read about active clinical trials, the spider venom research, and the full pre-clinical pipeline in the Knowledge Bank — including the STARFISH trial and the GsMTx-4 research.

Sources & Guidelines

Gutierrez C et al. Journal of Pain. 2026. Identifies tumor-secreted cytokines (HMGB1, CCL2, IL-6) and mechanosensitive Piezo channels as peripheral pain drivers in schwannomatosis; foundation for current STARFISH trial therapeutic targets.
Evans DG et al. ERN GENTURIS. European Journal of Human Genetics. 2022. Clinical management guidelines for schwannomatosis — surveillance imaging schedules, subtype-specific management, and surgical indications.
Plotkin SR et al. Genetics in Medicine. 2022. International consensus diagnostic criteria for schwannomatosis subtypes; prevalence estimates.
ClinicalTrials.gov NCT05684692 — STARFISH: A Platform Trial for Schwannomatosis Pain (anti-CGRP and anti-IL-6 arms).

✦

◈